Supplementary Tables – Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece

<strong>Supplementary Table 1: </strong>Fist-line Therapy Characteristics, Discontinuation and Switch to 2L. <strong>Supplementary Table 2: </strong>T790M mutation testing among patients progressing on or discontinued from 1L EGFR-TKI and Treatment Options. <strong>Supplementary Table 3: </strong>Third-, Fourth- and Fifth-line treatments.